The ‘Game of Epigenomics’ conference will celebrate the great diversity in the epigenomics field, reflecting both on DNA and protein modifications. The conference will host international and national leaders in the field, covering the spectrum of epigenomic research, presenting data from diverse model systems as well as clinical research and new insights in disease epigenomics. [...]

Targeting epigenetic modifiers and readers, particularly histone methyltransferases, demethylases and bromodomain-containing proteins have recently set the foundation for a new generation of anti-cancer drugs. Over the past few years, several companies have developed and successfully moved novel compounds targeting EZH2, DOT1L, LSD1, and a collection of BET bromodomain inhibitors into clinical studies. As these compounds [...]